Fred Turner on Curative’s Pandemic Pivot, Health Insurance and AI Automation

Fred Turner says the thrill of winning motivates him more than fear of losing. The Curative CEO recalls the pace of building a pandemic testing operation and says he has sought that momentum in later ventures. Harry Stebbings asks how his experience as a young British founder led him to Silicon Valley.

Turner says he struggled to obtain venture meetings in the UK as an undergraduate more than a decade earlier, while Silicon Valley investors were more receptive to an ambitious long-term outcome. He presents this as his own experience at that time, not a complete assessment of either startup ecosystem.

His first company, TL Biolabs, worked on cattle genetics. Turner says a farmer contacted him for testing after seeing his science-competition work; samples and a payment led to more customers. The company examined traits such as muscle development and dairy production.

Unable to raise the money he wanted in the UK, Turner visited San Francisco and met a Y Combinator alumnus. He applied shortly before the deadline and joined the summer 2016 batch. He describes the move as a turning point in his access to investors.

The company continued testing dairy cattle and raised a seed round, which Turner recalls as $1.65 million. He later concluded that the potential market for cattle tests was too small for the financing he wanted. The market calculation was his own rough estimate.

The team shifted the underlying testing technology toward human diagnostics, including a high-throughput laboratory and an at-home sexually transmitted infection test. Turner describes interest in antibiotic resistance and in testing that could inform treatment. The conversation does not establish that any specific test is suitable for an individual patient.

Turner next became interested in sepsis diagnostics and the difficulty of identifying serious infection promptly. He describes the company’s proposed testing approach and why speed mattered to him. His simplified explanations and numerical claims should not be used to diagnose or treat sepsis, which requires urgent professional care.

He says the earlier company, renamed Shield, wound down at the end of 2019 after a proposed financing fell through. According to Turner, it had only a few weeks of cash remaining. The interview presents his account of the negotiations, not an independently verified account from the other party.

During the wind-down, Turner says he sold a licensed laboratory asset for $150,000 and later acquired another laboratory for $27 million during the pandemic. He uses the contrast to illustrate how circumstances changed; the figures are his recollection and the assets were not the same laboratory.

Turner says losing a company after years of work was painful, but the experience taught him about hiring, management and building processes. He believes a second company is easier to build when a founder can apply lessons from earlier mistakes.

Curative began with a different sepsis-related idea: work with community hospitals to improve how patients were identified and managed. Turner describes a proposed service model and says a hospital pilot was being arranged. His assertions about clinical evidence and outcomes are his account, not proof that the proposed service worked.

He says an early investor backed the new business before knowing all the details. A planned pilot then stalled as a hospital prepared for COVID-19. Turner and his team initially thought testing might be a short temporary effort before returning to their original work.

Turner recalls reviewing early information about the outbreak and deciding it could be much larger than he had expected. His chief scientific officer had already developed a COVID test as a side project, he says. The immediate obstacle was finding an appropriate laboratory to run it.

After contacting people in his network, Turner found a licensed facility in Southern California. Curative initially formed a joint venture with its operator, bringing the test and expertise while the partner brought the laboratory. Turner says the company later bought out the partner to expand.

Early demand came from local public-safety agencies, Turner says. He recalls explaining the work to a sheriff who contacted him, then arranging testing for local agencies. His description of laboratory procedures is an account of that operation, not an independent safety assessment.

Turner says a social-media post by a collaborator led to a conversation with Los Angeles officials. The city initially wanted a pilot because Curative was not an established supplier. The company’s opportunity arose amid a rapidly changing and uncertain testing environment.

According to Turner, Los Angeles paid for completed tests quickly, with daily invoices and checks rather than a conventional long payment cycle. He says the cash flow helped the company purchase supplies and expand capacity. This is his description of the arrangement.

Turner recalls a large Florida contract for nursing-home staff testing, which he estimates at hundreds of millions of dollars. He says the state sought frequent testing across many facilities and that Curative bid when the logistics appeared difficult. The amount and outcomes are not independently verified in the interview.

He argues that established laboratories were optimized for efficiency at predictable volume, while a pandemic required a rapid increase in capacity. Curative therefore approached the supply chain differently, seeking materials outside the channels that many testing providers were already competing for.

Turner describes sourcing alternative swabs and choosing a different extraction approach to avoid bottlenecks. His point is about finding supplies that could scale, not a recommendation for laboratories to substitute materials without validation and regulatory review.

The captions and conversation give inconsistent figures for the peak number of tests in one day, so the exact total is unclear. Turner says the company grew from roughly seven to 7,000 employees in its first nine months; that figure is his account and is not independently audited here.

Rapid hiring required different processes. Turner describes brief interviews for some administrative positions while noting that certain laboratory roles required licensed personnel. He says many people wanted to contribute during the pandemic.

Turner estimates about $5 billion in COVID-testing revenue over three years. He says profitability varied sharply: surges filled laboratory capacity, while quieter periods left fixed facilities and staff underused. Revenue is not the same as profit, and the figures are founder-reported.

At peak demand, a drive-through site could process large volumes, he says. Between surges the organization still had to maintain staff and infrastructure so that capacity would be available when demand returned. Turner says the company lost money on tests in some of those low-volume periods.

Turner says roughly $500 million was later invested in the health-insurance business. He also describes administering approximately 2.5 million vaccinations and says that service lost money for the company. These figures are his account and are not independently verified in the interview.

The interviewer and Turner also discuss COVID vaccination and its changing benefits. Their brief exchange is not an assessment of vaccine effectiveness or a basis for individual medical decisions; those depend on current evidence and personal circumstances.

Turner says he expected testing to be temporary and had begun considering what might follow while the operation was still expanding. The team examined other laboratory and care businesses before becoming serious about insurance, which required time to secure the necessary licensing.

He says laboratory testing alone did not offer the scale he wanted, and the company considered buying hospitals. Turner ultimately judged a hospital-led approach difficult because of fragmented payer relationships. These are his strategic judgments and market estimates.

Turner argues that insurers influence what care is delivered because they determine which services they pay for. That view led Curative toward a health plan. Insurance design and care decisions also depend on clinical, regulatory and contractual factors beyond the simplified account in the interview.

Asked what he would change in US healthcare, Turner argues that consolidation among payers and hospital systems can distort negotiations. He says an independent primary-care doctor may be paid less than a comparable system-affiliated doctor. His comparison and explanation are his claims, not a universal price estimate.

The host asks where he would prefer to receive treatment. Turner praises access to advanced US care, but this is his opinion; access, quality and cost vary substantially by patient, location and health system.

Looking back at the insurance pivot, Turner says he did not anticipate how much AI would change administrative workflows. He describes insurance as coordinating payments, provider relationships and employer coverage, and says the company has redesigned many internal processes.

Turner reports that Curative automated much of provider credentialing with an agent, reducing the team assigned to that task. He gives a turnaround and cost comparison, but the interview does not independently establish accuracy, the extent of human review, regulatory compliance or patient safety outcomes.

He also describes using AI in claims processing and underwriting intake. Incoming employer information arrives in many formats, he says, and agents can generate code to convert files into a standard structure. These are accounts of internal workflows, not evidence that any claim decision is correct.

Turner says temporary, task-specific code can help process varied documents without asking every partner to reformat them. His claims about speed and scale are company-reported; handling sensitive health information still requires appropriate safeguards and review.

Asked whether software-as-a-service products are vulnerable, Turner says Curative replaced its Salesforce workflow with an internally built CRM and cancelled a contract he values at $600,000 a year. He says the replacement took about two months. The cost, timing and comparative performance are his account.

Stebbings asks whether building and maintaining software is worth the engineering time. Turner acknowledges that maintenance is challenging, but believes a custom system can fit a company’s workflow and be easier to change. He does not provide a full cost comparison including ongoing engineering, security and support.

Turner expects some infrastructure products and deeply integrated collaboration tools to remain harder to replace. He says Curative plans to reduce its software spending substantially as contracts renew, but this is a company plan rather than verified realized savings.

He describes building an internal claims system and migrating workflows from an external platform. The migration timeline and product-quality comparisons are his statements. The interview does not independently assess the system’s reliability, claims accuracy or compliance.

Turner predicts large insurers may move more slowly because organizational changes are difficult. He argues that automation can improve administrative efficiency, though his assumptions about competitors, staffing and future margins are forecasts rather than established results.

He discusses a medical-loss-ratio requirement and argues it can create unintended incentives. His characterization should not be read as a blanket cap on insurer profits: applicable rules vary by market and include administrative costs, quality activities and rebates, with details determined by the relevant law and plan.

Turner says Curative’s spending on Anthropic rose sharply as it found more applications. He also says some staff were repurposed rather than replaced. These are company-reported trends, and the interview does not provide independently verified spending or workforce data.

Building a provider network requires many contracts and relationships, Turner explains. He describes a team negotiating with providers and an email-based agent called Gwen that researches practices, reaches out and handles some negotiations within company-defined parameters.

Turner says the agent can help redline and sign certain agreements using his signature. He reports a substantial increase in contracts and lower per-contract cost, while saying people focus on larger relationships. The figures and legal controls are his account and are not independently verified.

Some providers are willing to negotiate by email, while larger groups may want calls and personal meetings, Turner says. He sees automation as a way to increase volume and free staff for those relationships, rather than simply perform the same volume with fewer people.

Turner estimates that the agent’s cost per contract is far below the previous human process and says a higher model price could still leave the workflow economical. The comparison is a company estimate, and the discussion does not disclose all oversight, infrastructure or quality costs.

The host asks how to distinguish work that expands with AI from work that disappears. Turner expects some back-office roles to be displaced, while investing in technical skills and human relationships. This is his forecast for particular workflows, not a reliable prediction for every worker or employer.

Turner says members still need access to a person, and provider groups and brokers often value personal relationships. He believes those relationships will remain important for significant contracts even as agents take on more administrative work.

He says the contracting agent operates against a lawyer-drafted template and internal limits. He describes allowing it to make some changes without a separate law-firm review. The interview does not establish that this process is appropriate for other organizations or that all contracts are free from errors.

Asked about Anthropic’s future value, Turner offers a very large valuation scenario. This is speculation, not an established valuation or investment advice. He also says automated, customized follow-up can increase the volume of provider outreach; the reported email count is his company’s claim.

Turner says Curative has around 650 employees and expects a smaller workforce in the short term as back-office workflows change, followed by possible longer-term growth. These are projections, not announced or verified employment outcomes.

He says care navigators will remain a human point of contact for members, with agents assisting with follow-up. The company believes this can increase their capacity, but the interview does not provide independent evidence of clinical benefit, quality or member experience.

Turner describes moving data visualizations from Looker to Snowflake with help from an agentic workflow. He says a small team completed much of the migration in a few months. This is his account of one project, not a general guarantee that data cleaning or migration is easy.

He predicts a growing role for agent supervisors. When automation expands the number of actions, even a small exception rate can produce many requests for human judgment. Turner says the company has experimented with agents supervising agents but still needs nuanced decisions about exceptions.

Turner expects AI capabilities to continue improving and recommends regularly testing tools to understand their current limits. He predicts displacement and discusses possible social responses, including some form of basic income. Those are policy opinions and forecasts, not settled outcomes.

He says trust is a practical barrier to granting agents authority. Curative debated whether its agent should sign contracts using his signature, he recalls, and he expects people to take time before delegating significant personal or business decisions.

Turner argues that AI could improve earnings in industries outside the largest technology firms by reducing administrative costs. His account of healthcare economics and future distribution of gains is a business opinion, not an independently established forecast.

He says Curative paid investors a dividend after the testing period and that they retained their shares, and reports a later $150 million financing at a $1.3 billion valuation. These are founder-reported transaction and return figures; the interview does not provide transaction documents.

Turner says he invests mainly in founders he knows and describes mixed results that are often too early to judge. He then introduces Subcritical, a nuclear fission company he co-founded with his wife. His discussion of its prospects is connected to his ownership and commercial interest.

Turner argues that nuclear deployment faces regulatory and construction challenges and describes his interest in an accelerator-driven subcritical system. His characterization of historical nuclear safety and regulation is his perspective; reactor safety depends on design, operation and independent regulatory assessment.

He says the proposed system would use an external accelerator to drive reactions in a subcritical assembly. He presents this as a potential safety advantage. A subcritical design does not by itself eliminate all hazards, and the interview supplies no independent demonstration or comprehensive safety evaluation.

Turner predicts more nuclear power and less coal in the future, and believes Subcritical could reach the market quickly. These are forecasts and company claims, not established deployment schedules or energy outcomes.

He describes using AI-assisted design to help engineers with some components while retaining human oversight of critical work. The proposed efficiency gains and staffing comparisons are his expectations, not independently validated safety or cost results.

Turner estimates a proposed 300-megawatt facility could cost roughly $1 billion to construct and says financing could combine debt and equity. The figure is an estimate for a proposed project, not a verified construction budget.

He discusses working with his wife and his personal experience of fatherhood. His views on when to have children reflect his own circumstances, not universal advice.

In a quick-fire discussion, Turner says he has become more optimistic about automating Curative’s back-office work and argues for evaluating the effects of regulation rather than only adding rules. Both are his views, and neither establishes a general result.

He predicts that spending on AI tools per engineer could rise substantially as engineers supervise more agents. The percentage and valuation implications raised in the conversation are speculative, not measured industry forecasts.

Turner credits early supporters who backed him when he was a young founder moving from the UK to Silicon Valley. He remembers an investor who encouraged the original cattle-testing company and says that willingness to take a chance mattered.

His closing advice is to seek different perspectives on difficult problems. During the testing effort, he says, military operations specialists, scientists and software developers approached the same challenges differently. Listening across those backgrounds helped the team find approaches he might not have considered alone.